About Progeneron

Progeneron is a first-of-its-kind multi-action product created to mitigate the progression and symptoms associated with Palmar Fibromatosis (Dupuytren's contracture). It has been the subject of a 90-day IRB safety study and a 180-day IRB efficacy study in which 95% of the population showed no signs of disease progression.


Clinical data, including studies, are available to physicians via our Progeneron Physician Portal and to the public via the Scharp Lacy Research Institute, a 501(c)(3) nonprofit focusing on Diabetes, Stem Cell, and Dupuytren's research.


About Dr. Scharp 

Progeneron was created by Dr. David Scharp, MD, who trained, taught, and worked at Washington University School of Medicine, St. Louis, MO, for 30 years as a Professor of Surgery and researcher in islet transplantation. Dr. Scharp has produced over 200 peer-reviewed publications and has been cited over 9000 times. Dr. Scharp has been awarded numerous NIH (National Institutes of Health) and JDRF (Juvenile Diabetes Research Foundation) research grants. Dr. Scharp has 13 issued patents and has been the Chief Medical Officer of companies specializing in clinical therapeutic solutions. Dr. Scharp is presently working on products covering a broad range of treatment protocols, including Dupuytren's Contracture, because of his personal experience with the disease. 


To view Dr. Scharp’s complete CV, please click here.


Our Commitment 

  • Clinical efficacy through in vitro and in vivo studies 
  • Safety through independent studies and testing
  • Scientific and medical advisory